Synthesis and molecular recognition studies on small-molecule inhibitors for thioredoxin reductase

Journal of Medicinal Chemistry

Volumn 57, Issue 19, 2014, Pages 8132-8139

  Zhang, Di ^a   Xu, Zhonghe ^b   Yuan, Jia ^c   Zhao, Ying Xi ^a   Qiao, Zeng Ying ^a   Gao, Yu Juan ^a   Yu, Guang Ao ^c   Li, Jingyuan ^b   Wang, Hao ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^c CENTRAL CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYNYL GROUP; GOLD; LEWIS ACID; OXIDOREDUCTASE INHIBITOR; PHOSPHINE; THIOREDOXIN REDUCTASE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; ELECTRON; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; HT 29 CELL LINE; HUMAN; MCF 7 CELL LINE; SYNTHESIS;

ANIMALS; ENZYME INHIBITORS; GOLD; HT29 CELLS; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84907895110     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5012098     Document Type: Article

References (35)

1. Tanaka, H.; Arakawa, H.; Yamaguchi, T.; Shiraishi, K.; Fukuda, S.; Matsui, K.; Takei, Y.; Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage Nature 2000, 404, 42-49
2. Lu, J.; Holmgren, A. Thioredoxin system in cell death progression Antioxid. Redox Signal. 2012, 17, 1738-1747
3. Baker, A.; Payne, C. M.; Briehl, M. M.; Powis, G. Thioredoxin, A gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo Cancer Res. 1997, 57, 5162-5167
4. Bindoli, A.; Rigobello, M. P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs Coord. Chem. Rev. 2009, 253, 1692-1707
5. Avval, F. Z.; Holmgren, A. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for mammalian s phase ribonucleotide reductase J. Biol. Chem. 2009, 284, 8233-8240
6. Arnér, E. S. J.; Holmgren, A. The thioredoxin system in cancer Semin. Cancer Biol. 2006, 16, 420-426
7. Nordberg, J.; Arner, E. S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system Free Radical Biol. Med. 2001, 31, 1287-1312
8. Eriksson, S. E.; Prast-Nielsen, S.; Flaberg, E.; Szekely, L.; Arnér, E. S. J. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy Free Radical Biol. Med. 2009, 47, 1661-1671
9. Benhar, M.; Forrester, M. T.; Hess, D. T.; Stamler, J. S. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins Science 2008, 320, 1050-1054
10. Kahlos, K.; Soini, Y.; Säily, M.; Koistinen, P.; Kakko, S.; Pääkkö, P.; Holmgren, A.; Kinnula, V. L. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma Int. J. Cancer 2001, 95, 198-204
11. Hedström, E.; Eriksson, S.; Zawacka-Pankau, J.; Arnér, E. S. J.; Selivanova, G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA Cell Cycle 2009, 8, 3584-3591
12. Nilsonne, G.; Sun, X.; Nyström, C.; Rundlöf, A.-K.; Potamitou Fernandes, A.; Björnstedt, M.; Dobra, K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress Free Radical Biol. Med. 2006, 41, 874-885
13. Powis, G.; Kirkpatrick, D. L.; Angulo, M.; Baker, A. Thioredoxin redox control of cell growth and death and the effects of inhibitors Chem. Biol. Interact. 1998, 111-112, 23-34
14. Witte, A.-B.; Anestal, K.; Jerremalm, E.; Ehrsson, H.; Arnér, E. S. J. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds Free Radical Biol. Med. 2005, 39, 696-703
15. Prast-Nielsen, S.; Cebula, M.; Pader, I.; Arnér, E. S. J. Noble metal targeting of thioredoxin reductase - covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin Free Radical Biol. Med. 2010, 49, 1765-1778
16. Lu, J.; Chew, E. H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12288-12293
17. Barnard, P. J.; Berners-Price, S. J. Targeting the mitochondrial cell death pathway with gold compounds Coord. Chem. Rev. 2007, 251, 1889-1902
18. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M. P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells Free Radical Biol. Med. 2007, 42, 872-881
19. Cox, A. G.; Brown, K. K.; Arner, E. S. J.; Hampton, M. B. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation Biochem. Pharmacol. 2008, 76, 1097-1109
20. Rigobello, M. P.; Scutari, G.; Boscolo, R.; Bindoli, A. Induction of mitochondrial permeability transition by auranofin, a Gold(I)-phosphine derivative Br. J. Pharmacol. 2002, 136, 1162-1168
21. Hashemy, S. I.; Ungerstedt, J. S.; Avval, F. Z.; Holmgren, A. Motexafin Gadolinium, A tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase J. Biol. Chem. 2006, 281, 10691-10697
22. Urig, S.; Fritz-Wolf, K.; Réau, R.; Herold-Mende, C.; Toith, K.; Davioud-Charvet, E.; Becker, K. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases Angew. Chem., Int. Ed. 2006, 45, 1881-1886
23. Meyer, A.; Bagowski, C. P.; Kokoschka, M.; Stefanopoulou, M.; Alborzinia, H.; Can, S.; Vlecken, D. H.; Sheldrick, W. S.; Wölfl, S.; Ott, I. On the biological properties of alkynyl phosphine gold (I) complexes Angew. Chem., Int. Ed. 2012, 51, 8895-8899
24. Rackham, O.; Nichols, S. J.; Leedman, P. J.; Berners-Price, S. J.; Filipovska, A. A gold (I) phosphine complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria Biochem. Pharmacol. 2007, 74, 992-1002
25. Rigobello, M. P.; Scutari, G.; Folda, A.; Bindoli, A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c Biochem. Pharmacol. 2004, 67, 689-696
26. Hickey, J. L.; Ruhayel, R. A.; Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Filipovska, A. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols J. Am. Chem. Soc. 2008, 130, 12570-12571
27. Sun, R. W.-Y.; Li, C. K.-L.; Ma, D.-L.; Yan, J. J.; Lok, C.-N.; Leung, C.-H.; Zhu, N.; Che, C.-M. Stable anticancer gold (III)-porphyrin complexes: effects of porphyrin structure Chem. - Eur. J. 2010, 16, 3097-3113
28. Ronconi, L.; Marzano, C.; Zanello, P.; Corsini, M.; Miolo, G.; Maccai, C.; Trevisan, A.; Fregona, D. Gold(III) Dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties J. Med. Chem. 2006, 49, 1648-1657
29. Messori, L.; Abbate, F.; Marcon, G.; Orioli, P.; Fontani, M.; Mini, E.; Mazzei, T.; Carotti, S.; O'Connell, T.; Zanello, P. Gold(III) Complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds J. Med. Chem. 2000, 43, 3541-3548
30. Che, C.-M.; Sun, R. W.-Y.; Yu, W.-Y.; Ko, C.-B.; Zhu, N.; Sun, H. Gold(iii) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells Chem. Commun. 2003, 1718-1719
31. Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies Med. Res. Rev. 2010, 30, 550-580
32. Fortman, G. C.; Poater, A.; Levell, J. W.; Gaillard, S.; Slawin, A. M.; Samuel, I. D.; Cavallo, L.; Nolan, S. P. A versatile gold synthon for acetylene C-H bond activation Dalton Trans. 2010, 39, 10382-10390
33. Xu, J.; Arnér, E. S. J. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase Biochem. Pharmacol. 2012, 83, 815-820
34. Cenas, N.; Nivinskas, H.; Anusevicius, Z.; Sarlauskas, J.; Lederer, F.; Arnér, E. S. J. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein J. Biol. Chem. 2004, 279, 2583-2592
35. Cheng, Q.; Antholine, W. E.; Myers, J. M.; Kalyanaraman, B.; Arnér, E. S. J.; Myers, C. R. The selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities J. Biol. Chem. 2010, 285, 21708-21723